2.41
-0.04 (-1.63%)
| Previous Close | 2.45 |
| Open | 2.47 |
| Volume | 181,979 |
| Avg. Volume (3M) | 304,648 |
| Market Cap | 119,293,800 |
| Price / Sales | 1.41 |
| Price / Book | 9.02 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2024 - 11 Nov 2024 |
| Profit Margin | -64.74% |
| Operating Margin (TTM) | -47.47% |
| Diluted EPS (TTM) | -1.16 |
| Quarterly Revenue Growth (YOY) | -1.50% |
| Total Debt/Equity (MRQ) | 380.68% |
| Current Ratio (MRQ) | 2.73 |
| Operating Cash Flow (TTM) | -51.20 M |
| Levered Free Cash Flow (TTM) | -34.91 M |
| Return on Assets (TTM) | -18.09% |
| Return on Equity (TTM) | -128.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Akoya BioSciences, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler® (formerly CODEX) and PhenoImager® (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 11.09% |
| % Held by Institutions | 70.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Peddock Capital Advisors, Llc | 30 Jun 2024 | 234,926 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (Craig-Hallum, 107.47%) | Hold |
| Median | 3.50 (45.23%) | |
| Low | 3.00 (Piper Sandler, 24.48%) | Buy |
| Average | 3.83 (58.92%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 2.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 19 Nov 2024 | 3.00 (24.48%) | Buy | 2.16 |
| Canaccord Genuity | 15 Nov 2024 | 3.50 (45.23%) | Buy | 2.41 |
| Craig-Hallum | 15 Nov 2024 | 5.00 (107.47%) | Hold | 2.41 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |